Approval of Novavax vaccine targeting JN.1 variant comes days after mRNA coronavirus vaccines from Pfizer-BioNTech and Moderna hit shelves.

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

The federal government’s move to pull hundreds of millions of dollars in funding for mRNA vaccines could be a shot in the arm ...

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Novavax’s updated COVID-19 vaccine is also authorized in the U.S. and the European Union, and is under review in other markets. The trade name Nuvaxovid has not been approved by the U.S. Food ...

The Novavax vaccine, which originally showed effectiveness in a nearly 30,000-person clinical trial, is still being sold under emergency use authorization in the U.S.

The FDA authorized an updated version of the protein-based Novavax COVID-19 vaccine for use in people 12 and up. Doses could be available by next week.

Novavax’s stock traded at more than $300 at times in 2021 as investors put high hopes in its development of a protein-based vaccine, a more traditional method compared with Pfizer and Moderna ...

Since the FDA greenlighted Novavax last month, clinical studies claiming less fevers and fatigue have driven people with long COVID and chronic fatigue syndrome to seek out the protein-based vaccine.

WASHINGTON — Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday.

The Food and Drug Administration (FDA) has authorized a new formulation of the COVID-19 vaccine made by the Maryland-based pharmaceutical company Novavax, the agency announced Tuesday (Oct. 3).

Shares of the Rockville-based vaccine maker Novavax surged more than 30 percent yesterday on news that the Spanish government plans to use its technology to protect people from the flu. Through a ...